Neolytica, a subsidiary of QPharma, brings global experience and cutting edge technology products and solutions that leverage data science and artificial intelligence.
Its comprehensive portfolio of offerings enables clients achieve effective pre and post launch medical communication, as also, optimize commercial and field force activities post launch.
Neolytica’s solutions and products portfolio deliver significant strategic and operational value to your Medical Affairs, Commercial Marketing, Market Access, and Commercial Sales functions.
Neolytica provides solutions that improve health and quality of life, and that advance the growth and success of our valued client in the global life science industry.
Our vision is to help Biopharma companies gain an unprecented level of support in their KOL engagement leading to an overall successful product placement.
We serve as stewards of quality — both in the delivery of our own compliance solutions, and in the innovative products and offerings we help our clients bring to market.
We hold our leadership, our personnel, our partners, and our clients to the highest standards — recognizing that we work together in serving patients and healthcare professionals who rely upon us.
We acknowledge that our company’s reputation depends on the empowerment of every individual to respond efficiently, to make decisions quickly, and to perform proactively in service to our clients.
We stand firmly behind our commitments — to serve our clients to the best of our ability, to engage with our community as good corporate citizens, and to demonstrate caring and concern for the lives of our employ KOLs and their families.
Badal Shah has transformed the approach to affecting successful outcomes inside the arena of thought leadership within health and life sciences. It was his vision to start a subsidiary company completely focused on Data analytics and Artificial intelligence. He will be the Managing Director of Neolytica and responsible for its growth and P&L.
Amit Sepaha has extensive experience in developing unique solution in the health & life science domain.
Achelle brings in robust experience and a strong scientific as well as analytical background.
Suhail Mughal services as Neolytica’s Chief Technology Officer, manifesting the technology leadership and strategies in delivering applications for all facets of the health and life sciences industry.
Lori Peters is both versatile and accomplished as a business professional with comprehensive consultative and account management experience.
Pat Den Boer founded QPharma (parent company of Neolytica) in 1994 and remains its President and Chief Executive Officer.
